Home » Newsletters » BioWorld Science

BioWorld Science

July 21, 2015

View Archived Issues

Aerosolized Ebola vaccine shows promising protective effect in nonhuman primates

Panther Biotechnology completes acquisition of Faulk Pharmaceuticals assets

Glypican-1 identified as potential diagnostic marker for pancreatic cancer

Heron Therapeutics resubmits Sustol NDA in U.S. for CINV

Cellceutix's brilacidin to advance to phase III for ABSSSI

Agenus acquires antibodies targeting CEACAM1

ASLAN and National Cancer Centre Singapore sign MOU to collaborate in gastric cancer

Fibrocell and Intrexon confirm IND filing of FCX-007 for recessive dystrophic epidermolysis bullosa

MGB Biopharma initiates phase I trial of MGB-BP-3 for C. difficile infections

Purdue Pharma patents morphinan analogs

Nanjing Sanhome Pharmaceutical discloses anti-HCV agents

Gilead introduces SYK inhibitors

Cadila divulges FFAR1 agonists

Bristol-Myers patents BRD4 inhibitors

BioMarin updates on development of talazoparib in breast cancer

Exelixis reports topline results from phase III trial of cabozantinib in renal cell carcinoma

DSMB recommends continuation of Graspa pancreatic cancer trial

Biotie starts phase III trial of tozadenant in Parkinson's disease

Nivolumab BMS approved in E.U. for squamous NSCLC

Novonco licenses rights to COH-29 from City of Hope

Purdue Pharma reports Nav1.7 channel blockers

Valeant agrees to acquire leading Egyptian pharmaceutical company

Virginia Commonwealth University patents NO-releasing allosteric Hb modifiers

SUVN-G3031 demonstrates procognitive effects without affecting sleep

TRV-101 reduces beta-amyloid and tau toxic aggregates in animal models of AD

CheckMate-025 study of Opdivo stopped early after meeting endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...